- Home
- AXIL vs BNR Comparison
AXIL vs BNR Comparison
Compare AXIL & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXIL
- BNR
- Stock Information
- Founded
- AXIL 2015
- BNR 2014
- Country
- AXIL United States
- BNR China
- Employees
- AXIL N/A
- BNR N/A
- Industry
- AXIL Package Goods/Cosmetics
- BNR Medical Specialities
- Sector
- AXIL Consumer Discretionary
- BNR Health Care
- Exchange
- AXIL Nasdaq
- BNR Nasdaq
- Market Cap
- AXIL 25.6M
- BNR 28.6M
- IPO Year
- AXIL N/A
- BNR 2020
- Fundamental
- Price
- AXIL $4.18
- BNR $3.75
- Analyst Decision
- AXIL
- BNR
- Analyst Count
- AXIL 0
- BNR 0
- Target Price
- AXIL N/A
- BNR N/A
- AVG Volume (30 Days)
- AXIL 6.3K
- BNR 21.3K
- Earning Date
- AXIL 10-10-2024
- BNR 11-29-2024
- Dividend Yield
- AXIL N/A
- BNR N/A
- EPS Growth
- AXIL 144.51
- BNR N/A
- EPS
- AXIL 0.24
- BNR N/A
- Revenue
- AXIL $27,243,542.00
- BNR $70,154,674.00
- Revenue This Year
- AXIL N/A
- BNR $52.90
- Revenue Next Year
- AXIL N/A
- BNR $48.35
- P/E Ratio
- AXIL $16.92
- BNR N/A
- Revenue Growth
- AXIL 7.30
- BNR N/A
- 52 Week Low
- AXIL $3.78
- BNR $2.62
- 52 Week High
- AXIL $14.00
- BNR $9.99
- Technical
- Relative Strength Index (RSI)
- AXIL 46.57
- BNR 59.38
- Support Level
- AXIL $4.00
- BNR $3.50
- Resistance Level
- AXIL $4.58
- BNR $3.89
- Average True Range (ATR)
- AXIL 0.22
- BNR 0.27
- MACD
- AXIL -0.00
- BNR 0.12
- Stochastic Oscillator
- AXIL 15.19
- BNR 82.19
About AXIL AXIL Brands Inc. Common Stock
AXIL Brands Inc is a company which is is a manufacturer and marketer of premium hearing enhancement and protection products, including ear plugs, earmuffs, and ear buds, under the AXIL brand. AXIL delivers top hearing enhancement, protection, & audio devices. From ultra comfortable fitting processes, to stereo quality sound performance, to reliable & durable engineering.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.